(Z08.0) Follow-up examination after surgery for malignant neoplasm

More details coming soon

Icon
887 941 in individuals diagnosis follow-up examination after surgery for malignant neoplasm confirmed

Diagnosis follow-up examination after surgery for malignant neoplasm is diagnosed Men are 35.35% more likely than Women

600 929

Men receive the diagnosis follow-up examination after surgery for malignant neoplasm

0 (less than 0.1%)

Died from this diagnosis.

100
95
90
85
80
75
70
65
60
55
50
45
40
35
30
25
20
15
10
5
0
287 012

Women receive the diagnosis follow-up examination after surgery for malignant neoplasm

0 (less than 0.1%)

Died from this diagnosis.

Risk Group for the Disease follow-up examination after surgery for malignant neoplasm - Men and Women aged 65-69

Icon
In Men diagnosis is most often set at age 0-95+
Icon
in in men, the disease manifests at any ageLess common in women the disease occurs at Age 95+
Icon
In Women diagnosis is most often set at age 0-94

Disease Features follow-up examination after surgery for malignant neoplasm

Icon
Absence or low individual and public risk
Icon

Follow-up examination after surgery for malignant neoplasm - what does this mean

A follow-up examination after surgery for a malignant neoplasm is a critical step in monitoring the patient's recovery and ensuring that any recurrence of the disease is detected and treated as soon as possible. this examination typically involves imaging tests, such as x-rays, ct scans, and mris, as well as blood tests to check for any markers of the disease. the frequency and type of follow-up examinations will vary depending on the type of cancer and the patient's individual situation.

What happens during the disease - follow-up examination after surgery for malignant neoplasm

The pathogenesis of follow-up examination after surgery for malignant neoplasms is to monitor the patient's recovery from the surgery and to detect any recurrence of the malignancy. this is done through a combination of physical examinations, imaging studies, laboratory tests, and tumor markers that can detect the presence of any remaining cancer cells or recurrence of the malignancy. the follow-up is also important to monitor any potential side effects of the surgery and to assess the patient's overall health.

Clinical Pattern

More details coming soon

How does a doctor diagnose

  • Physical examination
  • Laboratory tests
  • Imaging tests
  • Endoscopy
  • Biopsy
  • Tumor marker tests
  • Genetic testing

Treatment and Medical Assistance

Main Goal : Follow-up examination after surgery for malignant neoplasm
  • Assessment of patient's overall condition
  • Evaluation of wound healing
  • Assessment of lymph node status
  • Check for recurrence of the tumor
  • Monitoring for any side effects of the surgery
  • Periodic imaging studies to check for tumor recurrence
  • Regular blood tests to check for any changes in tumor markers
  • Periodic physical examination
Icon
6 Days of Hospitalization Required
Icon
Average Time for Outpatient Care Not Established

Follow-up examination after surgery for malignant neoplasm - Prevention

The best way to prevent recurrence of malignant neoplasms after surgery is to follow up with regular examinations, such as ct scans, mris, and pet scans. these examinations help detect any signs of recurrence early, allowing for early intervention and improved prognosis. additionally, regular follow-up visits with the doctor can help to monitor for any changes in the patient's condition.

Specified forms of the disease

(D81.0) Severe combined immunodeficiency [SCID] with reticular dysgenesis
(D81.1) Severe combined immunodeficiency [SCID] with low T- and B-cell numbers
(D81.2) Severe combined immunodeficiency [SCID] with low or normal B-cell numbers
(D81.3) Adenosine deaminase [ADA] deficiency
(D81.4) Nezelof syndrome
(D81.5) Purine nucleoside phosphorylase [PNP] deficiency
(D81.6) Major histocompatibility complex class I deficiency
(D81.7) Major histocompatibility complex class II deficiency
(D81.8) Other combined immunodeficiencies
(D81.9) Combined immunodeficiency, unspecified